An Open-Label, Dose-Escalating Study to Assess the Safety, Tolerability, Efficacy, Pharmacokinetics and Pharmacodynamics of Cysteamine Bitartrate Delayed-release Capsules (RP103) for Treatment of Children With Inherited Mitochondrial Disease

Trial Profile

An Open-Label, Dose-Escalating Study to Assess the Safety, Tolerability, Efficacy, Pharmacokinetics and Pharmacodynamics of Cysteamine Bitartrate Delayed-release Capsules (RP103) for Treatment of Children With Inherited Mitochondrial Disease

Completed
Phase of Trial: Phase II

Latest Information Update: 16 Nov 2017

At a glance

  • Drugs Mercaptamine bitartrate (Primary)
  • Indications Leigh disease; Mitochondrial disorders
  • Focus Therapeutic Use
  • Acronyms MITO-001
  • Sponsors Horizon Pharma USA; Raptor Pharmaceutical Corp
  • Most Recent Events

    • 15 Feb 2017 Status changed from recruiting to completed.
    • 25 Oct 2016 This trial was planned by Raptor Pharmaceutical Corp. The company has now been acquired by Horizon Pharma plc, according to a Horizon Pharmaceuticals media release.
    • 06 May 2016 According to a Raptor Pharmaceuticals media release, the second interim analysis occurred after 12 patients completed 24 weeks of treatment and indicated the trial should continue as planned.
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top